Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Pruritus: significant improvement · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Flumecinol changes pruritus: significant improvement compared with placebo (very low certainty).
1 finding from 1 review
Pruritus · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life · participants with cholestatic pruritus (CP)
1 finding from 1 review
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per participant ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher complete resolution of phimosis compared with placebo or no treatment (low certainty).
2 findings from 1 review
Partial resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher partial resolution of phimosis compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in retractability score · boys up to 18 years old with phimosis
It is very uncertain whether topical corticosteroids changes change in retractability score compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse effects (any) · boys up to 18 years old with phimosis
Topical corticosteroids showed no clear difference in adverse effects (any) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).
1 finding from 1 review
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Teriflunomide (Direct evidence; 1 RCT; 1169 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower teriflunomide (Direct evidence; 1 RCT; 1169 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
1 finding from 1 review
RR 0.57 [0.47, 0.68]
Studies not reported
High
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower cladribine (Direct evidence; 1 RCT; 1326 participants) (high certainty).
1 finding from 1 review